Chlorphenamine
From Wikipedia, the free encyclopedia
Chlorphenamine
|
|
Systematic (IUPAC) name | |
3-(4-chlorophenyl)-N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine |
|
Identifiers | |
CAS number | |
ATC code | R06 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C16H19ClN2 |
Mol. mass | 274.788 g/mol |
Physical data | |
Solubility in water | 0.55 g/100 mL, liquid mg/mL (20 °C) |
Pharmacokinetic data | |
Bioavailability | 25 to 50% |
Protein binding | 72% |
Metabolism | Hepatic (CYP2D6) |
Half life | 21-27 hours |
Excretion | Renal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status |
Pharmacist Only (S3)(AU) GSL(UK) OTC(US) |
Routes | Oral, IV, IM, SC |
Chlorphenamine (INN) or chlorpheniramine (USAN, former BAN), commonly marketed as its salt chlorphenamine maleate (CPM; Chlor-Trimeton®, Piriton®, Chlor-Tripolon®), is a first-generation antihistamine used in the prevention of the symptoms of allergic conditions such as rhinitis and urticaria.
Chlorphenamine has antidepressant properties, inhibiting reuptake of the neurotransmitter serotonin. Based on this knowledge, the Swedish company Astra AB was able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from chlorphenamine.
[edit] See also
[edit] References
- Bruce G. Charlton, Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring. Medical Hypotheses 2005; 65: 823-828.